Kyung Hee University Hospital at Gangdong, Seoul, Republic of Korea.
Integr Cancer Ther. 2020 Jan-Dec;19:1534735420908345. doi: 10.1177/1534735420908345.
Korean herbal medicine treatment (KHMT) involves treating with a combination of natural products, which have been used for thousands of years. Recently, it has been reported to be effective and safe in cancer patients. This case report demonstrates the efficacy of KHMT in a 49-year-old man with malignant pleural mesothelioma (MPM), a rare and highly aggressive cancer. The patient showed recurrent pleural effusion and was diagnosed with epithelioid MPM at cT3NxM0 stage III in December 2017. The multidisciplinary care team recommended multimodal treatment based on an extrapleural pneumonectomy, but he refused this because the treatment was aggressive and the effectiveness was unclear. He decided to undergo pemetrexed plus cisplatin chemotherapy if his condition worsened. He visited the Korean Medicine Cancer Center for alternative treatment options. A KHMT regimen, consisting of twice-daily Gunchil-dan and thrice-daily Bangam-tang, was initiated in December 2017. Since commencement of KHMT, computed tomography and X-ray imaging scans have shown no significant interval changes and progression. At 21 months into treatment (September 2019), no significant adverse events have occurred. Given that the median overall survival of patients with MPM is approximately 1 year, the ongoing progression-free survival of this patient for 21 months is relatively long. This case, therefore, suggests that KHMT is a potential treatment option for MPM patients.
韩医学治疗（KHMT）涉及使用天然产品的组合进行治疗，这些产品已经使用了数千年。最近，有报道称其对癌症患者有效且安全。本病例报告展示了 KHMT 对一名 49 岁男性恶性胸膜间皮瘤（MPM）患者的疗效，MPM 是一种罕见且高度侵袭性的癌症。该患者出现复发性胸腔积液，并于 2017 年 12 月被诊断为上皮样 MPM 分期为 cT3NxM0 期 III 期。多学科护理团队建议根据胸膜外肺切除术进行多模式治疗，但他拒绝了，因为这种治疗方法具有侵袭性，疗效不明确。如果病情恶化，他决定接受培美曲塞联合顺铂化疗。他前往韩国医学癌症中心寻求替代治疗方案。2017 年 12 月开始实施 KHMT 方案，包括每日两次的 Gunchil-dan 和每日三次的 Bangam-tang。自 KHMT 开始以来，计算机断层扫描和 X 射线成像扫描显示没有明显的间隔变化和进展。治疗 21 个月（2019 年 9 月）后，没有发生明显的不良事件。鉴于 MPM 患者的总体中位生存时间约为 1 年，该患者 21 个月的无进展生存时间相对较长。因此，该病例表明 KHMT 是 MPM 患者的一种潜在治疗选择。
